Twist Bioscience Corporation
TWST

NASDAQ > Medical - Diagnostics & Research
DCF:$35.26  |   P/E: -
$1.33(-2.77%)
Change
Rating:
Price: $47.94 USD
Market Cap: $2.77B

...Loading TWST Peers...





Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

    919 Employees

    CEO : Dr. Emily Marine Leproust Ph.D.

    Address : 681 Gateway Boulevard, South San Francisco,CA, US, - 94080,

Key ExcutivesDesignation
Dr. Aaron K. Sato Ph.D.Chief Scientific Officer
Dr. Michael Fero Ph.D.Chief Information Officer
Ms. Paula GreenSenior Vice President of Human Resources
Dr. William Charles Banyai Ph.D.Senior Vice President of Advanced Development, GM of Data Storage & Director
Mr. Siyuan ChenChief Technology Officer
Mr. Adam LaponisChief Financial Officer
Dr. Patrick John Finn Ph.D.President & Chief Operating Officer
Dr. Emily Marine Leproust Ph.D.Co-Founder, Chairman & Chief Executive Officer
Mr. Dennis Cho J.D.Senior Vice President, Chief Legal Officer & Corporate Secretary
Mr. Robert F. WernerVice President & Chief Accounting Officer